Compare · HIMS vs OPCH
HIMS vs OPCH
Side-by-side comparison of Hims & Hers Health Inc. (HIMS) and Option Care Health Inc. (OPCH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HIMS and OPCH operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- HIMS is the larger of the two at $7.96B, about 2.3x OPCH ($3.41B).
- Over the past year, HIMS is down 34.0% and OPCH is down 29.3% - OPCH leads by 4.7 points.
- HIMS has been more active in the news (5 items in the past 4 weeks vs 3 for OPCH).
- HIMS has more recent analyst coverage (25 ratings vs 15 for OPCH).
- Company
- Hims & Hers Health Inc.
- Option Care Health Inc.
- Price
- $34.37+0.03%
- $21.69+0.60%
- Market cap
- $7.96B
- $3.41B
- 1M return
- +23.88%
- +1.47%
- 1Y return
- -33.98%
- -29.30%
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 15
Hims & Hers Health Inc.
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, collagen protein, biotin, and teas in the wellness category; moisturizer, fragrances, face wash, and anti-wrinkle creams in the skincare category; condoms and lubricants in the sexual health category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. It also offers medical consultation services; and engages in the wholesale of non-prescription product sales to retailers. Hims & Hers Health, Inc. is based in San Francisco, California.
Option Care Health Inc.
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides immunoglobulin infusion therapies for the treatment of immune deficiencies; anti-infective therapies and services; home infusion services to treat heart failures; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders; and immunoglobulin infusion therapies. It also offers infusion therapies for bleeding disorders; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications. In addition, the company offers therapies that women need to survive and thrive through high-risk pregnancies; treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; and nursing services. The company is headquartered in Bannockburn, Illinois.
Latest HIMS
- Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026
- Chief Financial Officer Okupe Oluyemi exercised 7,163 shares at a strike of $5.01 and sold $261,351 worth of shares (7,163 units at $36.49) as part of a pre-agreed trading plan (SEC Form 4)
- Hims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Chief Medical Officer Carroll Patrick Harrison sold $830,410 worth of shares (23,726 units at $35.00), decreasing direct ownership by 12% to 181,861 units (SEC Form 4)
- Chief Financial Officer Okupe Oluyemi exercised 6,376 shares at a strike of $5.01 and sold $619,217 worth of shares (18,197 units at $34.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 284,321 units (SEC Form 4)
- Chief Financial Officer Okupe Oluyemi converted options into 71,616 shares and covered exercise/tax liability with 39,541 shares, increasing direct ownership by 12% to 296,142 units (SEC Form 4) to cover withholding tax
- Chief Medical Officer Carroll Patrick Harrison converted options into 25,926 shares and covered exercise/tax liability with 8,310 shares, increasing direct ownership by 9% to 205,587 units (SEC Form 4) (withholding tax)
- Chief Operating Officer Chi Michael covered exercise/tax liability with 47,699 shares, sold $441,850 worth of shares (14,027 units at $31.50) as part of a pre-agreed trading plan and converted options into 86,264 shares, increasing direct ownership by 6% to 432,124 units (SEC Form 4) (withholding obligation)
- Chief Policy Officer Autor Deborah M. covered exercise/tax liability with 15,396 shares and converted options into 32,919 shares, increasing direct ownership by 56% to 48,961 units (SEC Form 4)
- PAO Becklund Irene converted options into 15,971 shares, covered exercise/tax liability with 5,870 shares and sold $370,518 worth of shares (12,063 units at $30.72) as part of a pre-agreed trading plan, decreasing direct ownership by 22% to 6,790 units (SEC Form 4) (for tax liability)
Latest OPCH
- Option Care Health to Announce Second Quarter 2026 Financial Results and Host Conference Call
- EVP Sp Sales & Solutions Bhatia Prateek was granted 39,795 shares (SEC Form 4)
- SEC Form 3 filed by new insider Bhatia Prateek
- Goldman initiated coverage on Option Care Health with a new price target
- Option Care Health Appoints Robert Okunski as Vice President, Investor Relations
- Option Care Health Awarded TIME's World's Most Impactful Companies 2026 Ranking
- Director Bierbower Elizabeth D was granted 8,997 shares, increasing direct ownership by 38% to 32,871 units (SEC Form 4)
- Director Deckmann Natasha was granted 9,841 shares, increasing direct ownership by 44% to 32,002 units (SEC Form 4)
- Director Kraemer Harry M Jansen Jr was granted 21,076 shares, increasing direct ownership by 5% to 471,076 units (SEC Form 4)
- Director Pate R Carter was granted 8,997 shares, increasing direct ownership by 77% to 20,620 units (SEC Form 4)